GSK to partner with Vir for potential COVID-19 treatments, invest $250 million

(Reuters) – British drugmaker GlaxoSmithKline will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential antibody treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.
Vir’s shares rose… [+2247 chars]Source